JP2021532155A - トロスピウムを使用した過活動膀胱の治療方法 - Google Patents

トロスピウムを使用した過活動膀胱の治療方法 Download PDF

Info

Publication number
JP2021532155A
JP2021532155A JP2021504826A JP2021504826A JP2021532155A JP 2021532155 A JP2021532155 A JP 2021532155A JP 2021504826 A JP2021504826 A JP 2021504826A JP 2021504826 A JP2021504826 A JP 2021504826A JP 2021532155 A JP2021532155 A JP 2021532155A
Authority
JP
Japan
Prior art keywords
trospium
bladder
individual
day
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021504826A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021532155A5 (https=
Inventor
ギーシング，デニス
Original Assignee
タリス バイオメディカル エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by タリス バイオメディカル エルエルシー filed Critical タリス バイオメディカル エルエルシー
Publication of JP2021532155A publication Critical patent/JP2021532155A/ja
Publication of JP2021532155A5 publication Critical patent/JP2021532155A5/ja
Priority to JP2024121447A priority Critical patent/JP2024164020A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/02—General characteristics of the apparatus characterised by a particular materials
    • A61M2205/0216—Materials providing elastic properties, e.g. for facilitating deformation and avoid breaking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/02—General characteristics of the apparatus characterised by a particular materials
    • A61M2205/0266—Shape memory materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/10—Trunk
    • A61M2210/1078—Urinary tract
    • A61M2210/1085—Bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
JP2021504826A 2018-08-01 2019-07-31 トロスピウムを使用した過活動膀胱の治療方法 Pending JP2021532155A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024121447A JP2024164020A (ja) 2018-08-01 2024-07-26 トロスピウムを使用した過活動膀胱の治療方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862713414P 2018-08-01 2018-08-01
US62/713,414 2018-08-01
US201962850481P 2019-05-20 2019-05-20
US62/850,481 2019-05-20
PCT/US2019/044478 WO2020028554A1 (en) 2018-08-01 2019-07-31 Methods of treating overactive bladder using trospium

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024121447A Division JP2024164020A (ja) 2018-08-01 2024-07-26 トロスピウムを使用した過活動膀胱の治療方法

Publications (2)

Publication Number Publication Date
JP2021532155A true JP2021532155A (ja) 2021-11-25
JP2021532155A5 JP2021532155A5 (https=) 2022-08-10

Family

ID=69232612

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021504826A Pending JP2021532155A (ja) 2018-08-01 2019-07-31 トロスピウムを使用した過活動膀胱の治療方法
JP2024121447A Pending JP2024164020A (ja) 2018-08-01 2024-07-26 トロスピウムを使用した過活動膀胱の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024121447A Pending JP2024164020A (ja) 2018-08-01 2024-07-26 トロスピウムを使用した過活動膀胱の治療方法

Country Status (10)

Country Link
US (2) US11464734B2 (https=)
EP (1) EP3829582A4 (https=)
JP (2) JP2021532155A (https=)
KR (1) KR20210039403A (https=)
CN (1) CN112839653A (https=)
AU (1) AU2019315957A1 (https=)
BR (1) BR112021001337A2 (https=)
CA (1) CA3107461A1 (https=)
MX (1) MX2021001264A (https=)
WO (1) WO2020028554A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150250717A1 (en) 2014-03-06 2015-09-10 Taris Biomedical Llc Drug delivery systems and methods for treatment of bladder cancer with gemcitabine
SG10201913998YA (en) 2017-07-25 2020-03-30 Taris Biomedical Llc Methods of treating tumor metastasis
IL302714B1 (en) 2017-11-08 2026-01-01 Taris Biomedical Llc Methods for treating and maintaining bladder cancer using gemcitabine
CN112839653A (zh) 2018-08-01 2021-05-25 塔里斯生物医药公司 使用曲司氯铵治疗膀胱过度活动症的方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007517912A (ja) * 2004-01-13 2007-07-05 バソジェニックス ファーマシューティカルズ， インコーポレイテッド 心脈管および腎臓の適応症のための制御放出ｃｇｒｐ送達組成物
JP2008517031A (ja) * 2004-10-20 2008-05-22 ガルデルマ・リサーチ・アンド・デヴェロップメント 座瘡の維持療法におけるアダパレンの使用方法
JP2013534923A (ja) * 2010-06-22 2013-09-09 テバ ウィメンズ ヘルス インコーポレイテッド 過活動膀胱に関連する状態を治療する方法
JP2015529688A (ja) * 2012-09-18 2015-10-08 タリス バイオメディカル エルエルシー トロスピウムの使用による膀胱排尿機能障害及び他の下部尿路疾患の治療のための薬物送達システム及び方法
WO2017042370A1 (en) * 2015-09-10 2017-03-16 Assistance Publique - Hôpitaux De Paris Use of interleukin 2 for treating spondyloarthritis
JP2018070660A (ja) * 2016-10-27 2018-05-10 Ｅａファーマ株式会社 逆流性食道炎の再発抑制剤

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE172117T1 (de) * 1996-11-27 1998-10-15 Pfleger R Chem Fab Verwendung von trospiumchlorid zur herstellung eines arzneimittels zur behandlung von blasenkrankheiten
WO2004052440A1 (en) 2002-12-11 2004-06-24 Coloplast A/S A urinary catheter device with a pharmaceutically active composition
AU2004206846B2 (en) 2003-01-16 2009-05-28 University Of Rochester Quaternary antimuscarinic compounds for the treatment of bladder diseases
ES2322148T3 (es) 2004-08-11 2009-06-17 BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG Medicamentos que contienen anticolinergicos para el tratamiento en las vias urinarias.
US20060217405A1 (en) 2005-03-17 2006-09-28 Indevus Pharmaceuticals, Inc. Interstitial cystitis treatment
US7390816B2 (en) * 2005-06-21 2008-06-24 Bridge Pharma, Inc. Methods for treating urinary incontinence in patients suffering from memory disorders
JP5265359B2 (ja) 2005-08-11 2013-08-14 マサチューセッツ インスティテュート オブ テクノロジー 膀胱内薬物送達デバイスおよび方法
EP1933833B8 (en) 2005-09-02 2011-09-14 Theravida, Inc. Therapy for the treatment of overactive bladder
EP1967202A1 (en) 2007-03-05 2008-09-10 AEterna Zentaris GmbH Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity
US9586035B2 (en) 2007-12-11 2017-03-07 Massachusetts Institute Of Technology Implantable drug delivery device and methods for treatment of the bladder and other body vesicles or lumens
EA201170297A1 (ru) 2008-08-09 2011-08-30 Массачусетс Инститьют Оф Текнолоджи Имплантируемое устройство для доставки лекарственных средств и способ лечения мужской мочеполовой системы и окружающих тканей
CN102470237A (zh) 2009-06-26 2012-05-23 塔里斯生物医药公司 用于可植入药物递送装置的固体药物片剂
US9017312B2 (en) 2009-09-10 2015-04-28 Taris Biomedical Llc Implantable device for controlled drug delivery
PL3884988T3 (pl) 2009-12-17 2025-09-08 Taris Biomedical Llc Urządzenie implantowalne z tolerancją wewnątrzpęcherzową
DK2600800T3 (da) 2010-08-05 2020-11-16 Taris Biomedical Llc Indretning til lægemiddellevering i en ureterstent og kit dertil
JP5945544B2 (ja) 2010-10-06 2016-07-05 タリス バイオメディカル エルエルシー 時間選択的に生体吸収可能または崩壊可能な薬剤送達システムおよび方法
US9114111B2 (en) 2011-01-10 2015-08-25 Allergan, Inc. Methods for sustained treatment of bladder pain and irritative voiding
AU2012211960B2 (en) 2011-02-04 2016-12-01 Taris Biomedical Llc Implantable device for controlled release of low solubility drug
JP6463266B2 (ja) * 2012-08-31 2019-01-30 タリス バイオメディカル エルエルシー 膀胱癌の治療のためのオキサリプラチンを含む薬物送達システム及び方法
AU2013308465B2 (en) 2012-08-31 2018-05-17 Taris Biomedical Llc Drug delivery systems and methods for treatment of prostate disease comprising gemicitabine
EP2719374A1 (en) 2012-10-12 2014-04-16 Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen Drug delivery device
EP2964310A1 (en) 2013-03-05 2016-01-13 TARIS Biomedical LLC Drug delivery devices and methods for controlled drug release through device orifice
JP6697376B2 (ja) 2013-03-15 2020-05-20 タリス バイオメディカル エルエルシー 薬物送達のための薬物送達装置及び方法
PT2968880T (pt) 2013-03-15 2025-07-07 Taris Biomedical Llc Dispositivos de aplicação de fármaco com componente permeável a fármaco
CN113413393B (zh) 2013-08-19 2025-03-04 塔里斯生物医药公司 多单元药物递送装置和方法
BR112016010103A8 (pt) 2013-11-05 2018-01-30 Taris Biomedical Llc métodos, kits e dispositivos de suprimento de fármaco osmótico.
US20150250717A1 (en) 2014-03-06 2015-09-10 Taris Biomedical Llc Drug delivery systems and methods for treatment of bladder cancer with gemcitabine
JP6856380B2 (ja) 2014-06-26 2021-04-07 タリス バイオメディカル エルエルシー 弾性ポリマー−薬物マトリックス系を含む膀胱内薬物送達デバイス及び方法
KR102658706B1 (ko) 2015-04-23 2024-04-17 타리스 바이오메디컬 엘엘씨 약물-투과성 성분을 구비한 약물 전달 장치 및 방법
SG11201907033SA (en) 2017-02-01 2019-08-27 Taris Biomedical Llc In vivo drug delivery devices and methods for drug delivery
SG10201913998YA (en) 2017-07-25 2020-03-30 Taris Biomedical Llc Methods of treating tumor metastasis
CN112839653A (zh) 2018-08-01 2021-05-25 塔里斯生物医药公司 使用曲司氯铵治疗膀胱过度活动症的方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007517912A (ja) * 2004-01-13 2007-07-05 バソジェニックス ファーマシューティカルズ， インコーポレイテッド 心脈管および腎臓の適応症のための制御放出ｃｇｒｐ送達組成物
JP2008517031A (ja) * 2004-10-20 2008-05-22 ガルデルマ・リサーチ・アンド・デヴェロップメント 座瘡の維持療法におけるアダパレンの使用方法
JP2013534923A (ja) * 2010-06-22 2013-09-09 テバ ウィメンズ ヘルス インコーポレイテッド 過活動膀胱に関連する状態を治療する方法
JP2015529688A (ja) * 2012-09-18 2015-10-08 タリス バイオメディカル エルエルシー トロスピウムの使用による膀胱排尿機能障害及び他の下部尿路疾患の治療のための薬物送達システム及び方法
WO2017042370A1 (en) * 2015-09-10 2017-03-16 Assistance Publique - Hôpitaux De Paris Use of interleukin 2 for treating spondyloarthritis
JP2018070660A (ja) * 2016-10-27 2018-05-10 Ｅａファーマ株式会社 逆流性食道炎の再発抑制剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF CONTROLLED RELEASE, vol. 170, JPN6023026854, 2013, pages 161 - 166, ISSN: 0005099120 *

Also Published As

Publication number Publication date
US12133913B2 (en) 2024-11-05
MX2021001264A (es) 2021-07-02
AU2019315957A1 (en) 2021-02-18
US20230075003A1 (en) 2023-03-09
KR20210039403A (ko) 2021-04-09
EP3829582A1 (en) 2021-06-09
CN112839653A (zh) 2021-05-25
EP3829582A4 (en) 2022-04-27
WO2020028554A1 (en) 2020-02-06
US20200060966A1 (en) 2020-02-27
JP2024164020A (ja) 2024-11-26
BR112021001337A2 (pt) 2021-04-20
CA3107461A1 (en) 2020-02-06
US11464734B2 (en) 2022-10-11

Similar Documents

Publication Publication Date Title
US12133913B2 (en) Methods of treating overactive bladder using trospium
US11850244B2 (en) Drug delivery systems and methods for treatment of bladder dysfunction or disorder using trospium
RU2620032C2 (ru) Схема приема лидокаина для применения в продолжительном лечении боли в мочевом пузыре и раздражения при мочеиспускании
US10406335B2 (en) Drug delivery systems and methods for treatment of prostate
JP2021502347A (ja) ゲムシタビンを使用した膀胱癌の治療及び維持療法の方法
US10086034B2 (en) Compositions and methods for inducing urinary voiding and defecation
RU2832085C2 (ru) Способы лечения гиперактивного мочевого пузыря с применением троспия хлорида
BR122025013571A2 (pt) Usos de trópsio no tratamento de bexiga hiperativa e dispositivos intravesicais
HK40026424A (en) Drug delivery systems and methods for treatment of bladder voiding dysfunction and other lower urinary tract disorders by using trospium
HK40042011A (en) Drug delivery systems and methods for treatment of prostate
EA045084B1 (ru) Способы лечения и поддерживающей терапии рака мочевого пузыря с использованием гемцитабина

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220801

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220801

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230630

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230704

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230928

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231228

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240326

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240726

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240905

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240910